epocrates logo
epocrates logo
epocrates logo
  • 0

Herbs & Supplements

epocrates logo

Sign in to access our clinical decision support tools

Sign in Create Account

Formulary
No Formulary Selected

close

 

Select a medication above to begin.

ginkgo (Ginkgo biloba)

common name

Sections:

  • Entire Monograph
  • Reported Uses
  • Reported Doses
  • Cautions
  • Drug Interactions
  • Adverse Reactions
  • Synonyms
  • Other Info
  • Add to Interaction Check

Reported Uses

  • NOTE: see Herb & Supplement Effectiveness Rating Definitions table
  • ADHD [Insufficient Evidence]
  • age-related macular degeneration [Insufficient Evidence]
  • aging [Insufficient Evidence]
  • allergic rhinitis [Insufficient Evidence]
  • altitude sickness prevention [Insufficient Evidence]
  • angina [Insufficient Evidence]
  • anxiety [Possibly Effective]
  • asthma [Insufficient Evidence]
  • autism spectrum disorder [Insufficient Evidence]
  • bronchitis [Insufficient Evidence]
  • cancer prevention, ovarian [Insufficient Evidence]
  • cardiovascular disease prevention [Possibly Ineffective]
  • chronic fatigue syndrome [Insufficient Evidence]
  • CKD [Insufficient Evidence]
  • cocaine dependence [Insufficient Evidence]
  • cognitive decline, age-related [Possibly Ineffective]
  • cognitive function [Insufficient Evidence]
  • cognitive impairment [Insufficient Evidence]
  • cognitive impairment, chemo-related [Possibly Ineffective]
  • colorectal CA [Insufficient Evidence]
  • COPD [Insufficient Evidence]
  • cough [Insufficient Evidence]
  • dementia [Possibly Effective]
  • depression [Insufficient Evidence]
  • diabetes mellitus, type 2 [Insufficient Evidence]
  • diabetic retinopathy [Insufficient Evidence]
  • dry eye disease [Insufficient Evidence]
  • dyslexia [Insufficient Evidence]
  • fibromyalgia [Insufficient Evidence]
  • gastric CA [Insufficient Evidence]
  • glaucoma [Insufficient Evidence]
  • hearing loss [Possibly Effective]
  • hemorrhoids [Insufficient Evidence]
  • HTN [Possibly Ineffective]
  • HTN, pulmonary [Insufficient Evidence]
  • hypercholesterolemia [Insufficient Evidence]
  • intestinal parasite infection [Insufficient Evidence]
  • Lyme disease [Insufficient Evidence]
  • metabolic dysfunction-associated steatotic liver disease [Insufficient Evidence]
  • migraine prophylaxis [Insufficient Evidence]
  • multiple sclerosis [Possibly Ineffective]
  • pancreatic CA [Insufficient Evidence]
  • Parkinson disease [Insufficient Evidence]
  • peripheral arterial disease [Insufficient Evidence]
  • premenstrual syndrome [Possibly Effective]
  • quality of life [Insufficient Evidence]
  • radiation dermatitis [Insufficient Evidence]
  • radiation exposure [Insufficient Evidence]
  • Raynaud phenomenon [Insufficient Evidence]
  • scabies [Insufficient Evidence]
  • schizophrenia [Possibly Effective]
  • seasonal affective disorder [Insufficient Evidence]
  • sexual dysfunction [Insufficient Evidence]
  • sexual dysfunction, antidepressant-induced [Possibly Ineffective]
  • stroke [Possibly Effective]
  • tardive dyskinesia [Possibly Effective]
  • tinnitus [Possibly Ineffective]
  • vascular dementia [Possibly Effective]
  • venous thromboembolism [Insufficient Evidence]
  • vertigo [Possibly Effective]
  • vitiligo [Insufficient Evidence]
  • wound healing [Insufficient Evidence]

Copyright © 2026. All Rights Reserved. Republication or redistribution, including by framing or similar means, is prohibited without the prior written consent of copyright holder.

Select a medication above to begin.

Help
FDA Reporting Form
 
Download Epocrates from the App Store Download Epocrates from the Play Store
About Us Features Business Solutions Help & Feedback
© 2026 epocrates, Inc.    Terms of Use Privacy Policy Editorial Policy Do Not Sell or Share My Information